Immunomedics Inc. (NASDAQ:IMMU) rose 2.8% on Thursday . The stock traded as high as $2.60 and last traded at $2.59, with a volume of 1,642,196 shares. The stock had previously closed at $2.52.

IMMU has been the subject of several recent analyst reports. Jefferies Group raised Immunomedics from a “hold” rating to a “buy” rating and raised their price target for the stock from $1.50 to $5.00 in a report on Friday, May 6th. They noted that the move was a valuation call. Zacks Investment Research raised Immunomedics from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, April 5th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Immunomedics in a report on Tuesday, May 24th.

The company has a 50 day moving average price of $2.66 and a 200-day moving average price of $2.76. The stock’s market capitalization is $254.07 million.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. On average, analysts expect that Immunomedics Inc. will post ($0.57) EPS for the current fiscal year.

In other news, CEO Cynthia L. Goldenberg sold 41,441 shares of the stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $3.62, for a total value of $150,016.42. Following the transaction, the chief executive officer now owns 703,029 shares in the company, valued at approximately $2,544,964.98. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Cynthia L. Goldenberg sold 63,959 shares of the stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $4.09, for a total value of $261,592.31. Following the completion of the transaction, the chief executive officer now owns 703,029 shares in the company, valued at approximately $2,875,388.61. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP acquired a new position in shares of Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned approximately 0.90% of Immunomedics at the end of the most recent quarter.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.